Prevail raises $75M series A

Gene therapy and neurodegenerative disease company Prevail Therapeutics Inc. (New York, N.Y.) raised $75 million on March 8 in a series A round from OrbiMed Advisors, Pontifax Fund, RA Capital Management, EcoR1 Capital, Omega Funds, BVF Partners, Boxer Capital, Adage Capital Management and Alexandria Venture Investments.

Prevail launched in August with undisclosed seed funding from OrbiMed and the Silverstein Foundation for Parkinson’s with GBA. The newco has an exclusive, worldwide license from RegenxBio Inc. (NASDAQ:RGNX) to develop and commercialize adeno-associated virus-based gene therapies utilizing RegenxBio's NAV AAV9 vector to treat neurodegenerative diseases (see BioCentury, Aug. 11, 2017)...